Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Antisense oligonucleotides (ASOs) are a widely used form of gene therapy, which is translatable to multiple disorders. A major obstacle for ASO efficacy is its bioavailability for in vivo and in vitro studies. To overcome this challenge we use cell-penetrating peptides (CPPs) for systemic delivery of ASOs. One of the most advanced clinical uses of ASOs is for the treatment of spinal muscular atrophy (SMA). In this chapter, we describe the techniques used for in vitro screening and analysing in vivo biodistribution of CPP-conjugated ASOs targeting the survival motor neuron 2, SMN2, the dose-dependent modifying gene for SMA.

Original publication

DOI

10.1007/978-1-4939-9670-4_13

Type

Journal article

Journal

Methods Mol Biol

Publication Date

2019

Volume

2036

Pages

221 - 236

Keywords

Cell-penetrating peptides, Oligonucleotide delivery, Spinal muscular atrophy, Splice switching oligonucleotides, Survival motor neuron